- Home
- APP vs SNY Comparison
APP vs SNY Comparison
Compare APP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APP
- SNY
- Stock Information
- Founded
- APP 2012
- SNY 1994
- Country
- APP United States
- SNY France
- Employees
- APP N/A
- SNY N/A
- Industry
- APP EDP Services
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- APP Technology
- SNY Health Care
- Exchange
- APP Nasdaq
- SNY Nasdaq
- Market Cap
- APP 116.4B
- SNY 120.2B
- IPO Year
- APP 2021
- SNY N/A
- Fundamental
- Price
- APP $342.34
- SNY $50.74
- Analyst Decision
- APP Buy
- SNY Buy
- Analyst Count
- APP 20
- SNY 2
- Target Price
- APP $304.89
- SNY $57.50
- AVG Volume (30 Days)
- APP 4.0M
- SNY 2.3M
- Earning Date
- APP 02-12-2025
- SNY 01-30-2025
- Dividend Yield
- APP N/A
- SNY 4.01%
- EPS Growth
- APP 1098.41
- SNY N/A
- EPS
- APP 3.31
- SNY 4.00
- Revenue
- APP $4,289,729,999.00
- SNY $54,031,898,261.00
- Revenue This Year
- APP $41.33
- SNY $0.88
- Revenue Next Year
- APP $22.48
- SNY $6.28
- P/E Ratio
- APP $103.48
- SNY $25.52
- Revenue Growth
- APP 41.48
- SNY 6.01
- 52 Week Low
- APP $40.71
- SNY $45.22
- 52 Week High
- APP $417.64
- SNY $58.97
- Technical
- Relative Strength Index (RSI)
- APP 55.37
- SNY 63.19
- Support Level
- APP $307.07
- SNY $47.88
- Resistance Level
- APP $362.45
- SNY $51.08
- Average True Range (ATR)
- APP 16.82
- SNY 0.66
- MACD
- APP -2.16
- SNY 0.29
- Stochastic Oscillator
- APP 63.69
- SNY 89.67
About APP Applovin Corporation
AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.